Clinical Trials
12 trialsNCT07221357 2026-05-06
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07219238 2026-05-05
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GE Healthcare
Phase 2/3 Recruiting
NCT06280495 2026-04-20
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
Phase 2/3 Recruiting
NCT05786716 2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05770102 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT06958419 2025-08-07
Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2/3 Recruiting
NCT06441565 2025-07-30
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
Sun Yat-sen University
Phase 2/3 Recruiting
NCT05462613 2024-12-20
REPROGRAM-02
Centre Hospitalier Universitaire de Besancon
Phase 2/3 Recruiting
NCT04547166 2024-10-17
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
Shanghai Henlius Biotech
Phase 2/3 Recruiting
NCT06185556 2024-08-23
COLDFIRE-III
Amsterdam UMC, location VUmc
Phase 2/3 Recruiting
NCT06243393 2024-07-10
TROPHIT1
University Hospital Heidelberg
Phase 2/3 Recruiting